ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001952

Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay

Identifieur interne : 001952 ( PascalFrancis/Corpus ); précédent : 001951; suivant : 001953

Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay

Auteurs : A. Kastner ; M. T. Herrero ; E. C. Hirsch ; J. Guillen ; M. R. Luquin ; F. Javoy-Agid ; J. A. Obeso ; Y. Agid

Source :

Annals of neurology [ 0364-5134 ] ; 1994.

RBID : Pascal:94-0581048

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Pyridine(1-méthyl-4-phényl-1,2,3,6-tétrahydro), Tyrosine 3-monooxygenase, Neurone dopaminergique, Lévodopa, Antiparkinsonien, Locus niger, Chimiothérapie, Traitement, Effet biologique, Singe, Animal, Ganglioside GM1.

English descriptors

KwdEn :
- Animal, Antiparkinson agent, Biological effect, Chemotherapy, Dopaminergic neuron, Levodopa, Locus niger, Monkey, Parkinson disease, Treatment, Tyrosine 3-monooxygenase.

Abstract

Parkinson's disease is characterized by the degeneration of melanized dopaminergic neurons of the substantia nigra. The functional capacity of the surviving dopaminergic neurons is affected, as suggested by the subnormal levels of tyrosine hydroxylase messenger RNA and protein found in the remaining cells. The reduced expression of tyrosine hydroxylase may be due to either the evolving neurodegenerative process or its downregulation, possibly secondary to chronic levodopa treatment. The cellular content of tyrosine hydroxylase was determined in the mesencephalon from 16 Macaca fascicularis monkeys, wing a semiquantitative immunocytochemical method

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0364-5134`
A02	`01`			`@0 ANNED3`
A03		`1`		`@0 Ann. neurol.`
A05				`@2 36`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay`
A11	`01`	`1`		`@1 KASTNER (A.)`
A11	`02`	`1`		`@1 HERRERO (M. T)`
A11	`03`	`1`		`@1 HIRSCH (E. C.)`
A11	`04`	`1`		`@1 GUILLEN (J.)`
A11	`05`	`1`		`@1 LUQUIN (M. R.)`
A11	`06`	`1`		`@1 JAVOY-AGID (F.)`
A11	`07`	`1`		`@1 OBESO (J. A.)`
A11	`08`	`1`		`@1 AGID (Y.)`
A14	`01`			`@1 INSERM, U289 @2 75013 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 6 aut. @Z 8 aut.`
A20				`@1 206-214`
A21				`@1 1994`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16555 @5 354000040919720120`
A44				`@0 0000`
A45				`@0 46 ref.`
A47	`01`	`1`		`@0 94-0581048`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Parkinson's disease is characterized by the degeneration of melanized dopaminergic neurons of the substantia nigra. The functional capacity of the surviving dopaminergic neurons is affected, as suggested by the subnormal levels of tyrosine hydroxylase messenger RNA and protein found in the remaining cells. The reduced expression of tyrosine hydroxylase may be due to either the evolving neurodegenerative process or its downregulation, possibly secondary to chronic levodopa treatment. The cellular content of tyrosine hydroxylase was determined in the mesencephalon from 16 Macaca fascicularis monkeys, wing a semiquantitative immunocytochemical method
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pyridine(1-méthyl-4-phényl-1,2,3,6-tétrahydro) @2 NK @2 FX @5 04 @6 Pyridine(«1»-méthyl-«4»-phényl-«1,2,3,6»-tétrahydro)`
C03	`03`	`X`	`FRE`	`@0 Tyrosine 3-monooxygenase @2 FE @5 07 @6 Tyrosine «3»-monooxygenase`
C03	`03`	`X`	`ENG`	`@0 Tyrosine 3-monooxygenase @2 FE @5 07 @6 Tyrosine «3»-monooxygenase`
C03	`03`	`X`	`SPA`	`@0 Tyrosine 3-monooxygenase @2 FE @5 07 @6 Tyrosine «3»-monooxygenase`
C03	`04`	`X`	`FRE`	`@0 Neurone dopaminergique @5 10`
C03	`04`	`X`	`ENG`	`@0 Dopaminergic neuron @5 10`
C03	`04`	`X`	`SPA`	`@0 Neurona dopaminérgica @5 10`
C03	`05`	`X`	`FRE`	`@0 Lévodopa @5 13`
C03	`05`	`X`	`ENG`	`@0 Levodopa @5 13`
C03	`05`	`X`	`SPA`	`@0 Levodopa @5 13`
C03	`06`	`X`	`FRE`	`@0 Antiparkinsonien @5 14`
C03	`06`	`X`	`ENG`	`@0 Antiparkinson agent @5 14`
C03	`06`	`X`	`SPA`	`@0 Antiparkinsoniano @5 14`
C03	`07`	`X`	`FRE`	`@0 Locus niger @5 16`
C03	`07`	`X`	`ENG`	`@0 Locus niger @5 16`
C03	`07`	`X`	`SPA`	`@0 Locus níger @5 16`
C03	`08`	`X`	`FRE`	`@0 Chimiothérapie @5 17`
C03	`08`	`X`	`ENG`	`@0 Chemotherapy @5 17`
C03	`08`	`X`	`SPA`	`@0 Quimioterapia @5 17`
C03	`09`	`X`	`FRE`	`@0 Traitement @5 18`
C03	`09`	`X`	`ENG`	`@0 Treatment @5 18`
C03	`09`	`X`	`GER`	`@0 Aufbereiten @5 18`
C03	`09`	`X`	`SPA`	`@0 Tratamiento @5 18`
C03	`10`	`X`	`FRE`	`@0 Effet biologique @5 19`
C03	`10`	`X`	`ENG`	`@0 Biological effect @5 19`
C03	`10`	`X`	`SPA`	`@0 Efecto biológico @5 19`
C03	`11`	`X`	`FRE`	`@0 Singe @5 20`
C03	`11`	`X`	`ENG`	`@0 Monkey @5 20`
C03	`11`	`X`	`SPA`	`@0 Mono @5 20`
C03	`12`	`X`	`FRE`	`@0 Animal @5 21`
C03	`12`	`X`	`ENG`	`@0 Animal @5 21`
C03	`12`	`X`	`SPA`	`@0 Animal @5 21`
C03	`13`	`X`	`FRE`	`@0 Ganglioside GM1 @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Oxidoreductases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Oxidoreductases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Oxidoreductases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Enzyme`
C07	`02`	`X`	`ENG`	`@0 Enzyme`
C07	`02`	`X`	`SPA`	`@0 Enzima`
C07	`03`	`X`	`FRE`	`@0 Primates @2 NS`
C07	`03`	`X`	`ENG`	`@0 Primates @2 NS`
C07	`03`	`X`	`SPA`	`@0 Primates @2 NS`
C07	`04`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`04`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`04`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`05`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`05`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`05`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`06`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`06`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`06`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`07`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`07`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`07`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`08`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`08`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`08`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`09`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`09`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`09`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`10`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`10`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`10`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 283`

Format Inist (serveur)

NO :	PASCAL 94-0581048 INIST
ET :	Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay
AU :	KASTNER (A.); HERRERO (M. T); HIRSCH (E. C.); GUILLEN (J.); LUQUIN (M. R.); JAVOY-AGID (F.); OBESO (J. A.); AGID (Y.)
AF :	INSERM, U289/75013 Paris/France (1 aut., 2 aut., 3 aut., 6 aut., 8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 1994; Vol. 36; No. 2; Pp. 206-214; Bibl. 46 ref.
LA :	Anglais
EA :	Parkinson's disease is characterized by the degeneration of melanized dopaminergic neurons of the substantia nigra. The functional capacity of the surviving dopaminergic neurons is affected, as suggested by the subnormal levels of tyrosine hydroxylase messenger RNA and protein found in the remaining cells. The reduced expression of tyrosine hydroxylase may be due to either the evolving neurodegenerative process or its downregulation, possibly secondary to chronic levodopa treatment. The cellular content of tyrosine hydroxylase was determined in the mesencephalon from 16 Macaca fascicularis monkeys, wing a semiquantitative immunocytochemical method
CC :	002B02B06
FD :	Parkinson maladie; Pyridine(1-méthyl-4-phényl-1,2,3,6-tétrahydro); Tyrosine 3-monooxygenase; Neurone dopaminergique; Lévodopa; Antiparkinsonien; Locus niger; Chimiothérapie; Traitement; Effet biologique; Singe; Animal; Ganglioside GM1
FG :	Oxidoreductases; Enzyme; Primates; Mammalia; Vertebrata; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Tyrosine 3-monooxygenase; Dopaminergic neuron; Levodopa; Antiparkinson agent; Locus niger; Chemotherapy; Treatment; Biological effect; Monkey; Animal
EG :	Oxidoreductases; Enzyme; Primates; Mammalia; Vertebrata; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
GD :	Aufbereiten
SD :	Parkinson enfermedad; Tyrosine 3-monooxygenase; Neurona dopaminérgica; Levodopa; Antiparkinsoniano; Locus níger; Quimioterapia; Tratamiento; Efecto biológico; Mono; Animal
LO :	INIST-16555.354000040919720120
ID :	94-0581048

Links to Exploration step

Pascal:94-0581048

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay</title>
<author><name sortKey="Kastner, A" sort="Kastner, A" uniqKey="Kastner A" first="A." last="Kastner">A. Kastner</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Herrero, M T" sort="Herrero, M T" uniqKey="Herrero M" first="M. T" last="Herrero">M. T. Herrero</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guillen, J" sort="Guillen, J" uniqKey="Guillen J" first="J." last="Guillen">J. Guillen</name>
</author>
<author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name>
</author>
<author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J. A." last="Obeso">J. A. Obeso</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">94-0581048</idno>
<date when="1994">1994</date>
<idno type="stanalyst">PASCAL 94-0581048 INIST</idno>
<idno type="RBID">Pascal:94-0581048</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001952</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay</title>
<author><name sortKey="Kastner, A" sort="Kastner, A" uniqKey="Kastner A" first="A." last="Kastner">A. Kastner</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Herrero, M T" sort="Herrero, M T" uniqKey="Herrero M" first="M. T" last="Herrero">M. T. Herrero</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guillen, J" sort="Guillen, J" uniqKey="Guillen J" first="J." last="Guillen">J. Guillen</name>
</author>
<author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name>
</author>
<author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J. A." last="Obeso">J. A. Obeso</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="1994">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Antiparkinson agent</term>
<term>Biological effect</term>
<term>Chemotherapy</term>
<term>Dopaminergic neuron</term>
<term>Levodopa</term>
<term>Locus niger</term>
<term>Monkey</term>
<term>Parkinson disease</term>
<term>Treatment</term>
<term>Tyrosine 3-monooxygenase</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Pyridine(1-méthyl-4-phényl-1,2,3,6-tétrahydro)</term>
<term>Tyrosine 3-monooxygenase</term>
<term>Neurone dopaminergique</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Locus niger</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Effet biologique</term>
<term>Singe</term>
<term>Animal</term>
<term>Ganglioside GM1</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease is characterized by the degeneration of melanized dopaminergic neurons of the substantia nigra. The functional capacity of the surviving dopaminergic neurons is affected, as suggested by the subnormal levels of tyrosine hydroxylase messenger RNA and protein found in the remaining cells. The reduced expression of tyrosine hydroxylase may be due to either the evolving neurodegenerative process or its downregulation, possibly secondary to chronic levodopa treatment. The cellular content of tyrosine hydroxylase was determined in the mesencephalon from 16 Macaca fascicularis monkeys, wing a semiquantitative immunocytochemical method</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0>
</fA01>
<fA02 i1="01"><s0>ANNED3</s0>
</fA02>
<fA03 i2="1"><s0>Ann. neurol.</s0>
</fA03>
<fA05><s2>36</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KASTNER (A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HERRERO (M. T)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HIRSCH (E. C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GUILLEN (J.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LUQUIN (M. R.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>JAVOY-AGID (F.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>OBESO (J. A.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>AGID (Y.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>206-214</s1>
</fA20>
<fA21><s1>1994</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16555</s2>
<s5>354000040919720120</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>46 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>94-0581048</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Parkinson's disease is characterized by the degeneration of melanized dopaminergic neurons of the substantia nigra. The functional capacity of the surviving dopaminergic neurons is affected, as suggested by the subnormal levels of tyrosine hydroxylase messenger RNA and protein found in the remaining cells. The reduced expression of tyrosine hydroxylase may be due to either the evolving neurodegenerative process or its downregulation, possibly secondary to chronic levodopa treatment. The cellular content of tyrosine hydroxylase was determined in the mesencephalon from 16 Macaca fascicularis monkeys, wing a semiquantitative immunocytochemical method</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pyridine(1-méthyl-4-phényl-1,2,3,6-tétrahydro)</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>04</s5>
<s6>Pyridine(«1»-méthyl-«4»-phényl-«1,2,3,6»-tétrahydro)</s6>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tyrosine 3-monooxygenase</s0>
<s2>FE</s2>
<s5>07</s5>
<s6>Tyrosine «3»-monooxygenase</s6>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Tyrosine 3-monooxygenase</s0>
<s2>FE</s2>
<s5>07</s5>
<s6>Tyrosine «3»-monooxygenase</s6>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tyrosine 3-monooxygenase</s0>
<s2>FE</s2>
<s5>07</s5>
<s6>Tyrosine «3»-monooxygenase</s6>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Neurone dopaminergique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopaminergic neuron</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Neurona dopaminérgica</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Effet biologique</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Biological effect</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Efecto biológico</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Singe</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Monkey</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Mono</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Animal</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Animal</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Animal</s0>
<s5>21</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Ganglioside GM1</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>283</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 94-0581048 INIST</NO>
<ET>Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay</ET>
<AU>KASTNER (A.); HERRERO (M. T); HIRSCH (E. C.); GUILLEN (J.); LUQUIN (M. R.); JAVOY-AGID (F.); OBESO (J. A.); AGID (Y.)</AU>
<AF>INSERM, U289/75013 Paris/France (1 aut., 2 aut., 3 aut., 6 aut., 8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 1994; Vol. 36; No. 2; Pp. 206-214; Bibl. 46 ref.</SO>
<LA>Anglais</LA>
<EA>Parkinson's disease is characterized by the degeneration of melanized dopaminergic neurons of the substantia nigra. The functional capacity of the surviving dopaminergic neurons is affected, as suggested by the subnormal levels of tyrosine hydroxylase messenger RNA and protein found in the remaining cells. The reduced expression of tyrosine hydroxylase may be due to either the evolving neurodegenerative process or its downregulation, possibly secondary to chronic levodopa treatment. The cellular content of tyrosine hydroxylase was determined in the mesencephalon from 16 Macaca fascicularis monkeys, wing a semiquantitative immunocytochemical method</EA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Pyridine(1-méthyl-4-phényl-1,2,3,6-tétrahydro); Tyrosine 3-monooxygenase; Neurone dopaminergique; Lévodopa; Antiparkinsonien; Locus niger; Chimiothérapie; Traitement; Effet biologique; Singe; Animal; Ganglioside GM1</FD>
<FG>Oxidoreductases; Enzyme; Primates; Mammalia; Vertebrata; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Tyrosine 3-monooxygenase; Dopaminergic neuron; Levodopa; Antiparkinson agent; Locus niger; Chemotherapy; Treatment; Biological effect; Monkey; Animal</ED>
<EG>Oxidoreductases; Enzyme; Primates; Mammalia; Vertebrata; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Tyrosine 3-monooxygenase; Neurona dopaminérgica; Levodopa; Antiparkinsoniano; Locus níger; Quimioterapia; Tratamiento; Efecto biológico; Mono; Animal</SD>
<LO>INIST-16555.354000040919720120</LO>
<ID>94-0581048</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001952 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001952 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:94-0581048
   |texte=   Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay

Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys : effect of levodopa and GM1 ganglioside therpay

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri